InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
68,211.63
(
-1.58%
)
Post# of 253511
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: mcbio post# 170429

Saturday, 11/23/2013 2:20:39 PM

Saturday, November 23, 2013 2:20:39 PM

Post# of 253511
In AASLD data presented by Dr. Jacobson showed that patients with the Q80K polymorphism in cohort 1 had an SVR12 of 89% compared with 100% of those without Q80K. In cohort 2, this subgroup had SVR4=91% compared with 100% of those without Q80K. So, not bad at all but still patients with Q80K didn't do as good as those without it.

http://www.hivandhepatitis.com/hcv-treatment/experimental-hcv-drugs/4394-aasld-2013-simeprevir-sofosbuvir-produces-high-sustained-response-rates-for-hard-to-treat-patients
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up